CheckMate 274: Additional Efficacy Outcomes in Patients With MIBC

At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.

He shares whether there were any specific subgroups of patients who demonstrated a more pronounced benefit from nivolumab, as well as what challenges clinicians may face in translating these findings into real-world practice.